Chemistry:Vornorexant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | ORN-0829; TS-142 |
| Routes of administration | By mouth[1] |
| Drug class | Orexin antagonist |
| Pharmacokinetic data | |
| Elimination half-life | 1.3–3.3 hours[1][2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H22FN7O2 |
| Molar mass | 447.474 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea.[3][4][5] It is a dual orexin OX1 and OX2 receptor antagonist (DORA).[5][6] The medication is taken by mouth.[1] As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea.[3] It is under development by Taisho Pharmaceutical.[3]
Vornorexant has a time to peak of 2.5 hours and a relatively short elimination half-life of 1.3 to 3.3 hours.[1][2] It was designed to have a short half-life and duration in order to reduce next-day side effects like somnolence.[5]
See also
- Seltorexant – another investigational short-acting orexin receptor antagonist
- List of investigational sleep drugs § Orexin receptor antagonists
References
- ↑ 1.0 1.1 1.2 1.3 "Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study". Psychopharmacology 239 (7): 2143–2154. July 2022. doi:10.1007/s00213-022-06089-6. PMID 35296912.
- ↑ 2.0 2.1 "0146 Efficacy and Safety of Single Dose of TS-142, a Novel and Potent Dual Orexin Receptor Antagonist, in Insomnia Patients". Sleep 43 (Supplement 1): A58. April 2020. doi:10.1093/sleep/zsaa056.144. ISSN 0161-8105.
- ↑ 3.0 3.1 3.2 "TS 142 - AdisInsight". https://adisinsight.springer.com/drugs/800049420.
- ↑ "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opinion on Drug Metabolism & Toxicology 16 (11): 1063–1078. November 2020. doi:10.1080/17425255.2020.1817380. PMID 32901578.
- ↑ 5.0 5.1 5.2 "Hypocretins (orexins): The ultimate translational neuropeptides". Journal of Internal Medicine 291 (5): 533–556. May 2022. doi:10.1111/joim.13406. PMID 35043499.
- ↑ "Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia". Bioorganic & Medicinal Chemistry 28 (13): 115489. July 2020. doi:10.1016/j.bmc.2020.115489. PMID 32482533.
External links
 |  |
